Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Lead Statistician Joins OCTRU/CSM

OCTRU

OCTRU/CSM have recruited a new lead statistician to join the team.

INTACT Trial opens to recruitment

INTACT Trial opens to recruitment

OCTRU

INTACT is a feasibility, randomised controlled trial comparing intravenous iron to usual care in patients discharged from critical care with moderate-severe anaemia. The primary aim is to assess recruitment, randomisation and follow-up rates to inform the design of a future large multi-centre trial.

ASPECT Trial results

OCTRU

The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.

TARDOX Trial paper published

TARDOX Trial paper published

OCTRU

Published in The Lancet Oncology journal, the 10-patient phase 1 clinical trial used focussed ultrasound from outside the body to selectively heat liver tumours and trigger drug release from heat-sensitive carriers, known as thermosensitive liposomes. Building on over a decade of preclinical studies, the study demonstrated the ultrasound technique to be feasible, safe, and capable of increasing drug delivery to the tumour between two-fold and ten-fold in the majority of patients.

BOOST Trial finishes recruitment!

BOOST Trial finishes recruitment!

OCTRU

The BOOST Trial completed recruitment yesterday with the final recruit (number 438!) at Gloucester Care Services NHS Trust. The BOOST Trial is studying two different approaches to physiotherapy treatment for older people with back and leg pain due to lumbar spinal stenosis. Follow up assessment will continue for the next 12 months. Well done to the BOOST team and thank you to everyone taking part either as a patient or a centre.

New hope for patients with Dupuytren's disease

New hope for patients with Dupuytren's disease

OCTRU

The results are published today of a Phase 2a study conducted in OCTRU that investigated the effect of anti-TNF in patients with Dupuytren's disease

Load More